Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study
2018
• In HR+ breast cancer, randomized trials showed that: 1) adjuvant tamoxifen improved OS over no adjuvant endocrine therapy, and 2) adjuvant AI improved OS over tamoxifen. After 2005, AIs were recommended for postmenopausal women with HR+ BC.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
18
References
5
Citations
NaN
KQI